Eczema/Atopic Dermatitis

Editor's Choice

Creating a barrier: Novel therapy replenishes deficient lipids

Novel approach to atopic dermatitis therapy aims to repair the skin barrier by replenishing deficient lipids in individuals with atopic dermatitis and restoring the skin barrier to the physiologic status quo.

LATEST ARTICLES

Skin protection: New barrier cream protects without irritating

Las Vegas — A skin barrier protection cream (Tetrix, Coria Laboratories) appears to reduce exposure to skin allergens and irritants and decrease symptoms of eczematous dermatitis, according to James Q. Del Rosso, D.O., dermatology residency director, Valley Hospital Medical Center, Las Vegas.

Avoiding steroidal addiction: Consider calcineurin inhibitors first

Sheffield, England — New research data demonstrates that mild, moderate and potent strengths of topical corticosteroids (TCS) cause a thinning of the stratum corneum, particularly when applied for longer periods of time, whereas topical calcineurin inhibitors show no negative change in the integrity of the skin barrier.

Dermatitis flares: Consider contact sensitizers when treating eczema patients

Physicians should always consider contact sensitizers to be one of the causes of flaring atopic dermatitis, as well as those cases recalcitrant to therapy.

Pediatric dermatitis: Efalizumab succeeds where standard treatments fail

Severe cases of atopic dermatitis can prove to be extremely challenging to effectively treat.

Where other therapies fail, efalizumab may be one therapeutic option that can ultimately serve as the "go-to" therapy for those cases where standard therapies fall short of the mark.

Corticosteroid lotion: Study addresses need for more pediatric clinical trials

An open-label study demonstrated the efficacy and safety of a four-week course of hydrocortisone butyrate lotion 0.1 percent (Locoid Lotion, Triax) for treating moderate-to-severe atopic dermatitis in pediatric patients ages 3 months to less than 18 years. Disease improvement was rapid and dramatic, and the safety evaluation included Cosyntropin Stimulation Testing.